Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Pharmaceutical composition for ischemic stroke disease as well as preparation method and application of pharmaceutical composition

A technology of ischemic stroke and pharmaceutical preparations, applied in the field of drugs for preventing or treating ischemic stroke, including the pharmaceutical composition of salvianolic acid and human recombinant human prourokinase, which can solve the problem of blood brain Barrier damage, cerebral edema and hemorrhage, decreased vascular opening rate, etc., to achieve the effects of inhibiting cerebral microvascular exudation and cerebral hemorrhage, improving neurological scores, and reducing cerebral infarct volume

Pending Publication Date: 2021-12-31
TIANJIN TASLY ZHIJIAO PHARMA
View PDF0 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, for stroke patients 5 hours after the onset of stroke, alteplase thrombolysis not only reduces the vascular patency rate, but also often leads to damage to the blood-brain barrier, causing cerebral edema and hemorrhage, and the mortality rate reaches 5%.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Pharmaceutical composition for ischemic stroke disease as well as preparation method and application of pharmaceutical composition
  • Pharmaceutical composition for ischemic stroke disease as well as preparation method and application of pharmaceutical composition
  • Pharmaceutical composition for ischemic stroke disease as well as preparation method and application of pharmaceutical composition

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0068] The most preferred freeze-dried injection of the present invention, wherein the pharmaceutical active ingredient is salvianolic acid and human recombinant pro-urokinase, the weight ratio of the two is: salvianolic acid: human recombinant pro-urokinase=2:1

Embodiment 2

[0072] Take 2g of salvianolic acid and 1g of human recombinant pro-urokinase, dissolve them in 1000ml aqueous solution containing 100g of mannitol respectively, and put them into 2g vials respectively, totaling 500 vials, before capping, put them into a freeze-drying box , vacuum-dried for 24 hours, capped, and each of salvianolic acid and human recombinant pro-urokinase was packaged in a combined bottle to obtain the product.

Embodiment 3

[0074] Take 10g of salvianolic acid and 5g of human recombinant prourokinase, dissolve them in 1000ml aqueous solution containing 100g of mannitol respectively, and put them into 2g vials respectively, totaling 500 vials. Before sealing, put them into a freeze-drying box , vacuum-dried for 24 hours, capped, and each of salvianolic acid and human recombinant pro-urokinase was packaged in a combined bottle to obtain the product.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention relates to a pharmaceutical composition for an ischemic stroke disease as well as a preparation method and application of the pharmaceutical composition. The pharmaceutical composition mainly comprises salvianolic acid and human recombinant human pro-urokinase. The invention further relates to application of a combination of the salvianolic acid and the human recombinant human pro-urokinase in preparation of a medicine for preventing or treating ischemic stroke. The pharmaceutical composition disclosed by the invention can be used for preventing or treating the ischemic stroke and meanwhile reducing bleeding or bleeding tendency of a patient.

Description

technical field [0001] The present invention relates to a pharmaceutical composition for ischemic stroke and its preparation method and application, in particular to a pharmaceutical composition comprising salvianolic acid and human recombinant human prourokinase, and its preparation method And the use in the preparation of medicines for preventing or treating ischemic stroke diseases. Background technique [0002] Ischemic stroke is one of the major diseases that seriously threaten public health and medical finance. Alteplase is a thrombolytic drug recommended in the guidelines for the prevention and treatment of acute ischemic stroke in China, the United States, Europe, Japan and other countries. However, for stroke patients 5 hours after the onset of stroke, alteplase thrombolysis not only reduces the vascular patency rate, but also often leads to damage to the blood-brain barrier, causing cerebral edema and hemorrhage, with a mortality rate of 5%. Blood-brain barrier i...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K38/49A61K9/19A61P9/10A61P7/02A61K31/343A61K31/216
CPCA61K38/49A61K31/343A61K31/216A61K9/0019A61K9/19A61P9/10A61P7/02C12Y304/21073A61K2300/00
Inventor 韩晶岩王小乙李泉马治中
Owner TIANJIN TASLY ZHIJIAO PHARMA
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products